FR2760193B1 - Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules - Google Patents

Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules

Info

Publication number
FR2760193B1
FR2760193B1 FR9702420A FR9702420A FR2760193B1 FR 2760193 B1 FR2760193 B1 FR 2760193B1 FR 9702420 A FR9702420 A FR 9702420A FR 9702420 A FR9702420 A FR 9702420A FR 2760193 B1 FR2760193 B1 FR 2760193B1
Authority
FR
France
Prior art keywords
lipids
transfection
complexes
cells
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9702420A
Other languages
English (en)
Other versions
FR2760193A1 (fr
Inventor
Rainer Bischoff
Abdessiame Nazid
Yves Cordier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9702420A priority Critical patent/FR2760193B1/fr
Application filed by Transgene SA filed Critical Transgene SA
Priority to PCT/FR1998/000389 priority patent/WO1998037916A1/fr
Priority to AU67352/98A priority patent/AU727040B2/en
Priority to JP10537387A priority patent/JP2000510871A/ja
Priority to US09/171,845 priority patent/US6335199B1/en
Priority to CA002252942A priority patent/CA2252942A1/fr
Priority to EP98912565A priority patent/EP0948360A1/fr
Publication of FR2760193A1 publication Critical patent/FR2760193A1/fr
Application granted granted Critical
Publication of FR2760193B1 publication Critical patent/FR2760193B1/fr
Priority to US10/021,421 priority patent/US20020151070A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR9702420A 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules Expired - Fee Related FR2760193B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9702420A FR2760193B1 (fr) 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
AU67352/98A AU727040B2 (en) 1997-02-28 1998-02-27 New lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy
JP10537387A JP2000510871A (ja) 1997-02-28 1998-02-27 少なくとも一種の活性物質特にポリヌクレオチドを標的細胞中へ移送するのに使用できる新規脂質化合物およびこれを含む組成物、ならびに遺伝子治療における使用
US09/171,845 US6335199B1 (en) 1997-02-28 1998-02-27 Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use
PCT/FR1998/000389 WO1998037916A1 (fr) 1997-02-28 1998-02-27 Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
CA002252942A CA2252942A1 (fr) 1997-02-28 1998-02-27 Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
EP98912565A EP0948360A1 (fr) 1997-02-28 1998-02-27 Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US10/021,421 US20020151070A1 (en) 1997-02-28 2001-12-19 Lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9702420A FR2760193B1 (fr) 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules

Publications (2)

Publication Number Publication Date
FR2760193A1 FR2760193A1 (fr) 1998-09-04
FR2760193B1 true FR2760193B1 (fr) 1999-05-28

Family

ID=9504295

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9702420A Expired - Fee Related FR2760193B1 (fr) 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules

Country Status (7)

Country Link
US (2) US6335199B1 (fr)
EP (1) EP0948360A1 (fr)
JP (1) JP2000510871A (fr)
AU (1) AU727040B2 (fr)
CA (1) CA2252942A1 (fr)
FR (1) FR2760193B1 (fr)
WO (1) WO1998037916A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
AU772847B2 (en) * 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
KR100744237B1 (ko) * 1999-10-01 2007-07-30 리폭센 테크놀로지즈 리미티드 리포솜-포획된 디엔에이 경구용 백신
WO2001042200A1 (fr) * 1999-12-10 2001-06-14 Genzyme Corporation Amphiphiles cationiques pour administration intracellulaire de molecules therapeutiques
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
GB0222824D0 (en) * 2002-10-02 2002-11-06 Moredun Res Inst Bacteriophage-mediated immunisation II
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
EP2365962B1 (fr) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Lipidoïdes aminoalcool et leurs utilisations
CN102548396A (zh) * 2009-04-30 2012-07-04 贝克特里弗里特公司 用于表面消毒的组合物
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
SI2717893T1 (sl) 2011-06-08 2019-10-30 Translate Bio Inc Sestavki lipidnih nanodelcev in postopki za dostavo mRNA
EP3536787A1 (fr) 2012-06-08 2019-09-11 Translate Bio, Inc. Polynucléotides résistant aux nucléases et leurs utilisations
WO2014028487A1 (fr) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Lipidoïdes contenant des amines et leurs utilisations
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CA2928078A1 (fr) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Formulations de lipide pour l'administration d'arn messager
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
CN110511927A (zh) 2014-04-25 2019-11-29 川斯勒佰尔公司 信使rna的纯化方法
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
CN111588695A (zh) 2014-06-24 2020-08-28 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP3169310A1 (fr) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
CN110799529A (zh) 2017-04-22 2020-02-14 免疫治疗有限公司 改良lamp构建物
KR20240027895A (ko) 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
CN112930396A (zh) 2018-08-24 2021-06-08 川斯勒佰尔公司 用于纯化信使rna的方法
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009049A1 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
WO2022009051A1 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Procédé de détermination de la réactivité à un traitement du cancer de la prostate
WO2023201201A1 (fr) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Constructions de lamp bicistroniques comprenant des gènes améliorant la réponse immunitaire et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
AU701106B2 (en) 1995-06-07 1999-01-21 Promega Biosciences, Inc. Novel carbamate-based cationic lipids
NZ313839A (en) * 1995-07-21 1998-12-23 Genta Inc Amide-based cationic lipids
DE19607686A1 (de) 1996-02-29 1997-09-04 Chemicon Lab Gmbh Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung

Also Published As

Publication number Publication date
US6335199B1 (en) 2002-01-01
JP2000510871A (ja) 2000-08-22
WO1998037916A1 (fr) 1998-09-03
CA2252942A1 (fr) 1998-09-03
EP0948360A1 (fr) 1999-10-13
AU6735298A (en) 1998-09-18
US20020151070A1 (en) 2002-10-17
FR2760193A1 (fr) 1998-09-04
AU727040B2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
FR2760193B1 (fr) Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
PL341737A1 (en) Double capsule for administering active substances in multiple-dug therapies
FI972514A0 (fi) Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
PT869126E (pt) Derivados de ditiolano, sua preparacao e seus efeitos terapeuticos
ID26237A (id) Pengantaran zat aktif teraerosolisasi
PL327767A1 (en) Drugs containing known auxiliary substances and an active substance
DE69818443D1 (de) Aktives flüssigkeitslager
DE69821940D1 (de) Landwirtschaftlich aktive inhaltsstoffe enthaltende mikropartikel
DE60003938D1 (de) Wirkstoffe in hydrogel-mikroperlen
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
HU9800075D0 (en) Nucleic acid construct for expressing active substances wich can be activated by proteases, and preparation and use
PT1069890E (pt) Incorporacao de substancias activas em matrizes veiculares
NO994438D0 (no) Terapeutisk aktive diarylpropylaminer samt fremstilling og anvendelse derav
DE69710335D1 (de) Wirkstoffabgebende zusatzmittel und diese enthaltende reinigungsmittelstücke
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
DE69919490D1 (de) Puder mit fettlöslichem wirkstoff
PT1083790E (pt) Formulacoes de retardacao para substancias activas fitofarmaceuticas
DE69627880D1 (de) Diltiazemhaltige mikrogranulate mit verzögerter wirkstoffabgabe
PT1221845E (pt) Combinacoes de substancias activas com caracteristicas insecticidas e acaricidas
DZ2560A1 (fr) Préparations pharmaceutiques de cilansétrone stabilisées contre la racémisation.
PL351988A1 (en) Synthetic gene for expressing active retroviral protein in eukaryotes
ATE228575T1 (de) Wirkstoffkombinationen
DK0922703T3 (da) Substituerede heterocykliske benzocycloalkener og disses anvendelse som analgetisk virksomme stoffer
ZA983239B (en) Stable active human ob protein compositions and methods
FR2749514B1 (fr) Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament

Legal Events

Date Code Title Description
ST Notification of lapse